

Ivabradine improves angina-related quality of life

December 23 2015



(HealthDay)—For patients with angina pectoris, ivabradine is associated with improvements in certain parameters of quality of life (QoL), according to a study published online Dec. 22 in *Circulation: Cardiovascular Quality and Outcomes*.

Michal Tendera, M.D., from the Medical University of Silesia in Poland, and colleagues examined the effect of ivabradine on <u>angina</u>-related QoL in a subgroup of participants from the Study Assessing the Morbidity-Mortality Benefits of the I_f Inhibitor Ivabradine in Patients with Coronary Artery Disease (SIGNIFY) QoL substudy. Data were obtained for 4,187 <u>patients</u> (2,084 treated with ivabradine and 2,103 treated with placebo).

The researchers found that both treatment groups experienced



improvement in QoL. The primary outcome of change in physical limitation score at 12 months was 4.56 and 3.40 points for ivabradine and placebo, respectively (P = 0.085). At six months, the ivabradine-placebo difference in physical limitation score was significant (P = 0.048). Among ivabradine-treated patients, the visual analog scale and other Seattle Angina Questionnaire dimensions were higher at 12 months, particularly angina frequency (P "Treatment with ivabradine seems to be associated with improvements in self-reported QoL related to <u>angina pectoris</u>, notably in terms of angina frequency and disease perception," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Servier, which manufactures <u>ivabradine</u> and funded the study.

More information: Abstract

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Ivabradine improves angina-related quality of life (2015, December 23) retrieved 21 November 2023 from

https://medicalxpress.com/news/2015-12-ivabradine-angina-related-quality-life.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.